Abstract 559P
Background
BRAF mutated Non-Small Cell Lung Cancer (NSCLC) can be divided into three classes. Only class I (BRAF V600E/X) mutated NSCLC has FDA approved treatment options. The other two classes due to their unique mechanisms of oncogenesis do not have approved treatment. We explored any potential molecular differences between these three classes focused primarily on tumor mutation burden (TMB) to assess if immune checkpoint inhibitors (ICIs) is a possible option for all three classes of BRAF+ NSCLC.
Methods
We queried the public AACR GENIE database (version 13.1) that included TMB as performed by the AACR GENIC database.
Results
Out of 20,713 unique NSCLC patients, 3.96% were either class I, II, or III BRAF mutations (class I: 1.6%, class II: 1.3%; class III: 1.1%). An additional 1.7% non-class I-III BRAF mutations were identified but were not analyzed for this abstract. The mean age, sex, racial composition, and distribution of the BRAF mutations in all three classes are shown in the table. The median TMB (mt/MB) were 6.5, 9.5, and 10.3 for class I, II, and III BRAF+ NSCLC respectively. 30.5 % of V600E had TMB ≥ 10; 47.7% of class II had TMB ≥ 10; and 52.5% of class III had TMB ≥ 10. For those patients with TMB ≥ 10, the median TMB was 45, 28.9, 18.4 for class I, II, and III respectively with a 7.7% with range of median TMB between 50-100 (class I), 10.4% with median TMB range 100-500 (class II), 8.1% with median TMB range of 100-500 (class III). There is no statistical significance in the mean or median TMB by pair-wise comparison of all three classes. Genomic co-alterations were being analyzed and will be updated. Table: 559P
Class I (N = 324) | Class II (N = 260) | Class III (N = 236) | |
Mean age (SD) | 67.4+/-10.5 | 69.0+/-8.9 | 67.6+/-9.6 |
Sex (%) | Female (58.6%) | Female (56.5%) | Female (49.6%) |
Race | White (70.7%)Black (8.3%)Asian (4.9%)Unknown (16%) | White (80.4%)Black (6.9%)Asian (2.3%)Unknown (10.4%) | White (77.5%)Black (10.6%)Asian (2.1%)Unknown (9.7%) |
Mutations | V600E (99.1%) V600K (0.6%) V600D (0.3%) | G469A/V/R (64.6%) K601E/N (23.5%) G464V/E (9.6%) L597Q (2.6%) | G466V/E/A (39.0%) D594N/G/A/H (29.2%) N581S/I (20.3%) G596R (8.5%) G469E (1.7%) V459L (0.85%) D287H (0.4%) S467L (0.4%) |
Conclusions
BRAF+ NSCLC patients are elderly. Class III has the highest median TMB followed by class II then class I. Based on TMB distribution, there is extensive heterogeneity within each three classes of BRAF+ NSCLC. Many BRAF+ NSCLC tumors have a high proportion having TMB ≥ 10. ICI is a potential treatment option for substantial proportion of all three classes of BRAF+ NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Nagasaka: Financial Interests, Personal, Advisory Board: AstraZeneca, Caris Life Sciences, Daiichi Sankyo, Novartis, EMD Serono, Janssen, Lilly, Pfizer, Genentech, Mirati, Regeneron, Silverback; Financial Interests, Personal, Invited Speaker: Takeda, Blueprint; Financial Interests, Personal, Other, Travel: AnHeart. S.I. Ou: Financial Interests, Personal, Invited Speaker: Pfizer, Roche; Financial Interests, Personal, Advisory Board: JNJ/Janssen, Elevation Oncology, AnHeart Therapeutics; Financial Interests, Personal, Ownership Interest: MBrace Therapeutics, BlossomHill Therapeutics; Financial Interests, Institutional, Local PI: Pfizer, Mirati, JNJ/Janssen, Merus, Revolution Medicine, Nuvalent. All other authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract